Bacchus Vascular, Inc. Announces The U.S. Clearance For The TRELLIS-8 Isolated Thrombolysis Catheter
10/19/2005 5:13:09 PM
SANTA CLARA, Calif.--(BUSINESS WIRE)--March 28, 2005--Bacchus Vascular, Inc. announces the recent U.S. Food and Drug Administration (FDA) clearance of the TRELLIS(R)-8 Peripheral Infusion System. The TRELLIS-8 is an advanced drug infusion catheter designed for the treatment of Deep Vein Thrombosis (DVT) and Arterial Occlusions by enabling targeted delivery of clot-dissolving drugs. The TRELLIS-8 clearance is for the infusion of physician specified fluids, including thrombolytics, into the peripheral vasculature.
"Interventionalists are demanding a tool to treat DVT efficiently and cost-effectively," said Dr. Thomas Fogarty, Stanford cardiovascular surgeon and founder of Bacchus Vascular. "Our engineers designed the TRELLIS-8 to treat DVT in a single procedure and not require a hospital to invest in capital equipment."
comments powered by